Dynamic changes in quality of life after three first-line therapies for EGFR
mutation-positive advanced non-small-cell lung cancer

Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer

Background: Three different tyrosine kinase inhibitors have been approved as first-line therapies for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer with similar overall survival. This study determined dynamic changes in quality of life (QoL) for patien...

Full description

Bibliographic Details
Main Authors:	Szu-Chun Yang, Chien-Chung Lin, Wu-Wei Lai, Sheng-Mao Chang, Jing-Shiang Hwang, Wu-Chou Su, Jung-Der Wang
Format:	Article
Language:	English
Published:	SAGE Publishing 2018-02-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758834018755072

Similar Items

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
by: Po-Lan Su, et al.
Published: (2018-09-01)

First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
by: Po‐Lan Su, et al.
Published: (2021-02-01)

Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.
by: Szu-Chun Yang, et al.
Published: (2020-01-01)

The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis.
by: Wei-Yuan Chang, et al.
Published: (2018-01-01)

Efficacy and resistance of EGFR-TKIs for first-line treatment for compound EGFR mutations positive non-small cell lung cancer
by: GUAN Xuhui, et al.
Published: (2022-12-01)

<sup>18</sup>F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs
by: Yu-Erh Huang, et al.
Published: (2022-03-01)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
by: Chih-Jen Yang, et al.
Published: (2017-05-01)

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study
by: Jun-Feng Liu, et al.
Published: (2023-03-01)

An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer
by: Yuexiao Qi, et al.
Published: (2022-08-01)

Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
by: Sheng‐Yuan Wang, et al.
Published: (2022-01-01)

The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
by: Isamu Okamoto, et al.
Published: (2010-09-01)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022-09-01)

Observation on the clinical efficacy and side effects of EGFR-TKI ± chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma
by: Jianping Zheng, et al.
Published: (2022-12-01)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
by: Eun Young Kim, et al.
Published: (2018-12-01)

LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab
by: Yahua Wu, et al.
Published: (2023-12-01)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
by: Tomoaki Sonoda, et al.
Published: (2018-01-01)

Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma
by: Hui ZHANG, et al.
Published: (2015-11-01)

Outcomes of salvage lung resections in advanced EGFR‐mutant lung adenocarcinomas under EGFR TKIs
by: Ying‐Yuan Chen, et al.
Published: (2021-10-01)

HDAC inhibition decreases the expression of EGFR in colorectal cancer cells.
by: Chia-Wei Chou, et al.
Published: (2011-01-01)

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands
by: Verduyn S, et al.
Published: (2012-09-01)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas.
by: Jaeyoung Cho, et al.
Published: (2016-01-01)

Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers
by: Takahiro Akita, et al.
Published: (2024-04-01)

Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells
by: Paulina Skupin-Mrugalska, et al.
Published: (2020-09-01)

Non-bacterial thrombotic endocarditis during treatment for EGFR mutation positive lung cancer
by: S. Moore, et al.
Published: (2022-03-01)

Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma
by: Xiaoyu Han, et al.
Published: (2021-03-01)

Germ-line mutations in epidermal growth factor receptor (<it>EGFR) </it>are rare but may contribute to oncogenesis: A novel germ-line mutation in <it>EGFR </it>detected in a patient with lung adenocarcinoma
by: Menéndez Primitiva, et al.
Published: (2011-05-01)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
by: Chih‐Hsun Wu, et al.
Published: (2019-10-01)

Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
by: Ying Wu, et al.
Published: (2024-04-01)

Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer
by: Elena V Reutova, et al.
Published: (2019-09-01)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
by: Zhengyu Yang, et al.
Published: (2021-08-01)

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
by: Chun-Yao Huang, et al.
Published: (2023-05-01)

Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas
by: Wu Shafei, et al.
Published: (2010-07-01)

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
by: Ding-Yu Rao, et al.
Published: (2023-04-01)

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
by: Bin-Chi Liao, et al.
Published: (2018-04-01)

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
by: Mai Suzuki, et al.
Published: (2024-02-01)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
by: Svetlana V. Odintsova, et al.
Published: (2020-07-01)

CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas
by: Xiaoyu Han, et al.
Published: (2020-07-01)

A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment
by: Hideharu Kimura, et al.
Published: (2019-11-01)

EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review
by: Chang-Hung Chen, et al.
Published: (2022-11-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)